Product Pipeline for New Pharmaceutical Drugs

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

  • Abrocitinib (JAK1 Inhibitor):  Atopic Dermatitis 
  • Braftovi® (encorafinib)  + Erbitux® (cetuximab):  1st line BRAF-mutant Metastatic Colorectal Cancer 
  • Braftovi® (encorafinib) + Mektovi® (binimetinib) + Keytruda® (pembrolizumab):  BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
  • COVID-19 Vaccine:  COVID-19 Infection (in collaboration with BioNTech)
  • Fidanacogene elaparvovec (PF-06838435) (Gene Therapy, coagulation factor IX):  Hemophilia
  • Fordadistrogene movaparvovec (PF-06939926) (Gene Therapy):  Duchenne Muscular Dystrophy
  • Giroctocogene fitelparvovec (PF-07055480) (Gene Therapy, coagulation factor VIII):  Hemophilia
  • Marstacimab (PF-06741086) (Tissue Factor Pathway Inhibitor):  Hemophilia
  • Prophylactic Vaccine:  Clostridioides difficile infection
  • Prophylactic Vaccine:  Invasive and Non-Invasive Pneumococcal infections (adult, pediatric) 
  • Prophylactic Vaccine:  Meningococcal Infections (adolescent and young adults)
  • Prophylactic Vaccine:  Respiratory Syncytial Virus Infection (maternal) (FAST TRACK)
  • Relugolix combination: Uterine Fibroids, Endometriosis
  • Ritlecitinib (JAK3/TEC Inhibitor):  Alopecia Areata 
  • Sasanlimab (PF-06801591) + BCG:  Non-Muscle-Invasive Bladder Cancer
  • Somatrogon (PF-06836922):  Growth Hormone Deficiency (adult, pediatric)
  • Talzenna® (talazoparib) + Xtandi® (enzalutamide):  1st Line Metastatic Castration-Resistant Prostate Cancer 
  • Tanezumab:  Chronic Pain due to Moderate-to-Severe Osteoarthritis; Cancer Pain
  • Xtandi® (enzalutamide):  Non-metastatic High-Risk Castration Sensitive Prostate Cancer

Pipeline Snapshot as of May 4, 2021

  • Discovery Projects
  • Phase 1
    30
  • Phase 2
    38
  • Phase 3
    22
  • Registration
    10
  • Total100
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
abrocitinib (PF-04965842)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK1 Inhibitor
Go to clinical trial
Atopic Dermatitis (PRIORITY REVIEW, BREAKTHROUGH - U.S., E.U.) Registration New Molecular Entity Small Molecule
aztreonam-avibactam (PF-06947387)
Therapeutic Area:
Hospital (Anti-Infectives)
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Beta Lactam/Beta Lactamase Inhibitor
Treatment of infections caused by Gram-negative bacteria Phase 3 New Molecular Entity Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/CMP-001 for Head and Neck Cancer (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) Phase 2 Product Enhancement Biologic
Braftovi (encorafinib) + Erbitux® (cetuximab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor and anti EGFR
Go to clinical trial
1st line BRAF-mutant Metastatic Colorectal Cancer Phase 3 Product Enhancement Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor andMEK inhibitor
1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer Phase 2 Product Enhancement Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib) + Keytruda®(pembrolizumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor andMEK inhibitor and anti PD-1
BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
Project advanced
Phase 3 Product Enhancement Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical TYK2/JAK1 Inhibitor
Atopic Dermatitis Phase 2 New Molecular Entity Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical TYK2/JAK1 Inhibitor
Psoriasis Phase 2 New Molecular Entity Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
TYK2/JAK1 Inhibitor
Psoriatic Arthritis Phase 2 Product Enhancement Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
TYK2/JAK1 Inhibitor
Alopecia Areata Phase 2 Product Enhancement Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
TYK2/JAK1 Inhibitor
Lupus Phase 2 Product Enhancement Small Molecule
danuglipron (PF-06882961)
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist
Diabetes Mellitus-Type 2 Phase 2 New Molecular Entity Small Molecule
danuglipron (PF-06882961)
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist
Obesity
Project advanced
Phase 2 Product Enhancement Small Molecule
danuglipron (PF-06882961) + PF-06865571
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist; Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis
Project advanced
Phase 1 New Molecular Entity Small Molecule
Dekavil
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
IL-10
Rheumatoid Arthritis (Biologic) Phase 2 New Molecular Entity Biologic